News

Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine ...
Editas' share price has struggled due to clinical setbacks, but recent focus on in-vivo gene editing offers renewed hope and ...
By using a protein called Cas9 to find and remove a damaged portion of a genetic sequence and then replace it using a gene-editing biotechnology based on clustered regularly interspaced short ...
In July 2025, Novartis Pharmaceuticals announced a phase III study to assess efficacy and safety of crizanlizumab (5 mg/kg) ...
We need a dedicated framework that clarifies the rules, requirements and incentives for those building personalized ...
Berkeley is getting a boost, launching a dedicated space for expanding companies that have outgrown their starter homes. | A biotech incubator at the University of California, Berkeley is getting a ...
Intellia Therapeutics plunged 29% on safety concerns but rebounded as the full story emerged, showing the value of patience. Read why NTLA stock is a buy.
When it comes to groundbreaking biotech advancements, Eric Faw Intellia is a name you might wanna keep an eye on. This article gonna dive deep into Eric Faw ...
Intellia develops drugs with CRISPR-based therapies, pioneering in vivo therapies ... NTLA is a likely beneficiary of Eli Lilly's(NYSE: LLY) acquisition of Verve Therapeutics(NASDAQ: VERV), a ...